Photo of Pamela Forrest

Pamela Forrest

Pamela Forrest has over 25 years of experience advising clients on a broad range of FDA regulatory issues. Her practice focuses on FDA medical device matters, including premarket notification, premarket approval, product recalls, Medical Device Reporting (MDR), Quality System Regulation (QSR) compliance, establishment registration and device listing, labeling and promotion, import/export issues, and clinical trial requirements.

Pamela frequently advises medical device manufacturers on responses to FDA enforcement actions, including Form FDA-483 observations and Warning Letters. She has extensive experience working with firms to draft written responses, develop and implement corrective actions, and prepare for re-inspection.

Pamela regularly assists medical device manufacturers, investment banks, and private equity firms with complex due diligence evaluations regarding the FDA compliance status of acquisition targets. She also frequently counsels start-up medical device firms on market entry strategies, and works with firms to identify the appropriate regulatory pathway and shepherd them through the FDA regulatory process.

Pamela has written and spoken extensively on various aspects of FDA regulation of medical devices, and has testified before several State legislative committees regarding medical device legal and regulatory issues.

As we kick off 2022, several recent developments from FDA suggest that this year could be pivotal for the Agency’s digital health priorities.  From new FDA offices and artificial intelligence guidance, to FDA’s user fee commitments and must-pass legislation in Congress, this post outlines five key issues to watch in
Continue Reading 5 Digital Health Issues to Watch at FDA in 2022